Cytosorbents Corporation (CTSO): Price and Financial Metrics


Cytosorbents Corporation (CTSO)

Today's Latest Price: $8.36 USD

0.17 (2.08%)

Updated Nov 27 1:00pm

Add CTSO to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 143 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

CTSO Stock Summary

  • With a price/sales ratio of 9.89, Cytosorbents Corp has a higher such ratio than 85.06% of stocks in our set.
  • As for revenue growth, note that CTSO's revenue has grown 54.57% over the past 12 months; that beats the revenue growth of 90.55% of US companies in our set.
  • Cytosorbents Corp's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -22.77%, greater than the shareholder yield of only 14.06% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Cytosorbents Corp, a group of peers worth examining would be FLDM, TWOU, LEAF, MBII, and OBLN.
  • CTSO's SEC filings can be seen here. And to visit Cytosorbents Corp's official web site, go to www.cytosorbents.com.

CTSO Stock Price Chart Interactive Chart >

Price chart for CTSO

CTSO Price/Volume Stats

Current price $8.36 52-week high $11.74
Prev. close $8.19 52-week low $3.49
Day low $8.21 Volume 145,400
Day high $8.48 Avg. volume 576,589
50-day MA $8.31 Dividend yield N/A
200-day MA $8.37 Market Cap 360.95M

Cytosorbents Corporation (CTSO) Company Bio


CytoSorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its platform blood purification technology incorporating a proprietary adsorbent polymer technology. The company was founded in 1997 and is based in Monmouth Junction, New Jersey.


CTSO Latest News Stream


Event/Time News Detail
Loading, please wait...

CTSO Latest Social Stream


Loading social stream, please wait...

View Full CTSO Social Stream

Latest CTSO News From Around the Web

Below are the latest news stories about Cytosorbents Corp that investors may wish to consider to help them evaluate CTSO as an investment opportunity.

CytoSorbents Highlights CytoSorb Use in Sepsis Patients During Sepsis Awareness Month and World Sepsis Day 2020

MONMOUTH JUNCTION, N.J., Sept. 11, 2020 /PRNewswire/ -- CytoSorbents Corporation (Nasdaq: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac surgery patients…

PR Newswire | September 11, 2020

CytoSorbents' "CTC Registry" is actively enrolling

CytoSorbents ([[CTSO]] -4.1%) announces that the U.S.-based "CytoSorb Therapy in COVID-19 ICU Patients," ("CTC") Registry, is now live and actively enrolling patients.Multiple U.S. centers are taking part in the registry, with the first patient already successfully included by the University of Chicago Medicine.The CTC registry has been designed to uniformly capture...

Seeking Alpha | September 8, 2020

CytoSorbents Announces the "CytoSorb Therapy in COVID-19 ICU Patients" (CTC) Registry Is Actively Enrolling

/PRNewswire/ -- CytoSorbents Corporation (Nasdaq: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to…

PR Newswire | September 8, 2020

CytoSorbents inks deal to commercialize CytoSorb in Northeast, Mid-Atlantic, and Florida region

CytoSorbents (CTSO) has entered into separate agreements with InvoSurg Inc. and Surgical Partners to commercialize CytoSorb under its FDA Emergency Use Authorization ((EUA)) in adult, critically-ill, COVID-19 patients with imminent or confirmed respiratory failure.Covering 15 states, Surgical Partners and InvoSurg will work with CytoSorbents to sell and distribute CytoSorb in Florida,...

Seeking Alpha | August 17, 2020

CytoSorbents Achieves Milestone of More than 100,000 CytoSorb Treatments Delivered Cumulatively To Date

MONMOUTH JUNCTION, N.J., Aug. 3, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announces…

PR Newswire | August 3, 2020

Read More 'CTSO' Stories Here

CTSO Price Returns

1-mo 9.28%
3-mo -0.95%
6-mo -19.38%
1-year 109.52%
3-year 19.43%
5-year 12.97%
YTD 117.14%
2019 -52.35%
2018 24.31%
2017 19.27%
2016 -2.15%
2015 -44.02%

Continue Researching CTSO

Want to see what other sources are saying about Cytosorbents Corp's financials and stock price? Try the links below:

Cytosorbents Corp (CTSO) Stock Price | Nasdaq
Cytosorbents Corp (CTSO) Stock Quote, History and News - Yahoo Finance
Cytosorbents Corp (CTSO) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7624 seconds.